STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear® in Mexico and First Commercial Placements
HORSHAM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic...
EHR
REPEAT – MEDIA ADVISORY: Patients join Day of Action at Ontario Legislature to demand action on complaints about private clinics’ charges
TORONTO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- On Wednesday October 29, patients who have been wrongfully charged for surgeries and...
Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness
Policy opinion leaders believe a biological attack is both more likely and easier to execute than a nuclear strike, highlighting...
Evidence Against Evidence: CERN-IEEE FPGA vs. Crosetto 3D-Flow, a Breakthrough Invention Recognized 32 Years Ago That Could Have, and Can Still, Save Billions of Euros and Millions of Lives
Science vs. Consensus: An urgent call to CERN, IEEE, and the scientific community to engage with verifiable evidence, fulfill scientific...
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in...
ISPE Names CSL Behring the 2025 ISPE Facility of the Year Awards (FOYA) Overall Winner for its Project Aurora Plasma Base Fractionation Facility (Facility F)
CSL Behring has been honored with this prestigious award recognizing innovation and excellence in pharmaceutical facility projects, as the FOYA...
Honey Health Raises $7.8M to Automate Healthcare’s Back Office With Autonomous AI Agents
The all-in-one AI back office platform is already working with 100+ organizations, saving them millions in administrative overhead MOUNTAIN VIEW,...
Sales Training Software Market to Reach $12.2 Billion by 2034 Globally, at 13.5% CAGR: Allied Market Research
The global sales training software market is experiencing rapid growth due to increase in demand for voice-enabled applications, advancements in natural...
INVO Fertility Partners with Heidi Health to Bring AI-Powered Tools to INVO’s Wisconsin Fertility Institute
MIDDLETON, Wis. and SARASOTA, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the...
INVO Fertility Partners with Heidi Health to Bring AI-Powered Tools to INVO’s Wisconsin Fertility Institute
MIDDLETON, Wis. and SARASOTA, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the...
INVO Fertility Partners with Heidi Health to Bring AI-Powered Tools to INVO’s Wisconsin Fertility Institute
MIDDLETON, Wis. and SARASOTA, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the...
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer
SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer
SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer
SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer
REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing...
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer
REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing...
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer
REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing...
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing...
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass.,...
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker data informing...